Biography for Tracy Staton
Tracy Staton, Senior Editor
Tracy Staton is the editor of FiercePharma and FiercePharmaMarketing. She has been a freelance writer for eight years, but before that served as editor of the Dallas Business Journal, editor of Texas Business magazine, and a senior editor at American Way, the inflight magazine of American Airlines. She is based in Vermont, and can be reached at firstname.lastname@example.org or find her on LinkedIn.
Articles by Tracy Staton
When it comes to Big Pharma's reputation, "average" says it all. That's the story from the research firm Reputation Institute, which perennially puts major drugmakers right smack in the middle of its scorecard. In other words, pharma is a C student.
A small but growing number of patients is racking up big drug bills in the U.S. On a per-patient basis, it's staggering: Some 576,000 Americans generated more than $50,000 in prescription drug costs each last year, according to a report from Express Scripts. And nearly 140,000 of them totted up drug bills of $100,000 or more.
Not satisfied with the way its new purchase Auxilium had handled Stendra marketing, Endo plans to relaunch the erectile dysfunction med, which it sells in partnership with Vivus. Endo is doubling the size of the Stendra salesforce, rolling out a new DTC effort, and keeping a close eye on inventory levels, which had built up too much for its taste.
Afrezza wasn't expected to be the spinach that would give Sanofi's diabetes business instant, superhuman strength. But the inhaled insulin, launched in February under a marketing deal with MannKind, was supposed to help fuel sales growth.
Four out of 5 drugmakers sued by the city of Chicago escaped the lawsuit, thanks to a Friday court ruling. The case against Purdue Pharma, however, will go on--albeit in a diminished way.
Who are the most profitable companies in healthcare? Drug companies, with 7 out of 10 slots on a ranking by profit margin. Who are the most profitable drug companies? You might scratch your heads at all but a couple of names.
No surprise that the health industry is setting records, M&A-wise. According to PricewaterhouseCoopers, life sciences companies inked 35 deals worth $166.3 billion--more than all of 2014's transactions combined--in Q1.
The FDA is taking its off-label marketing debate public. After an onslaught of lawsuits and citizen petitions against drug-marketing restrictions--all citing the First Amendment--the agency will hold a public meeting this summer to talk about off-label promos and free speech, Reuters reports.
Twenty-seven drug brands took 20% price increases last year, and dozens saw prices at least double over the past 5 years, Bloomberg reports. Once again, the usual suspects top the price-increase lists. And diabetes products are conspicuously present.
Mystery solved: Novo Nordisk heir apparent Kåre Schultz didn't just up and leave the Danish drugmaker. He left for the top job at crosstown colleague Lundbeck, vacant since that CEO stepped down in disgrace in November.